Background
==========

Health economic evaluations are conducted to inform resource allocation decisions. Economic evaluation has been defined as "the comparative analysis of alternative courses of action in terms of both their costs and their consequences" \[[@B1]\]. All economic evaluations assess costs, but approaches to measuring and valuing the consequences of health interventions may differ (see Figure [1](#F1){ref-type="fig"}).
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Economic evaluations have been widely applied in health policy, including the assessment of prevention programmes (such as vaccination, screening, and health promotion), diagnostics, treatment interventions (such as drugs and surgical procedures), organisation of care, and rehabilitation. Economic evaluations are increasingly being used for decision making and are an important component of programmes for health technology assessment internationally \[[@B2]\].

Reporting challenges and shortcomings in health economic evaluations
--------------------------------------------------------------------

Compared with clinical studies, which report the consequences of an intervention only, economic evaluations require more reporting space for additional items, such as resource use, costs, preference related information, and cost effectiveness results. This creates challenges for editors, reviewers, and those who wish to scrutinise a study's findings \[[@B3]\]. There is evidence that the quality of reporting of economic evaluations varies widely and could potentially benefit from improved quality assurance mechanisms \[[@B4],[@B5]\].

With the increasing number of publications available, and opportunity costs from decisions based on misleading study findings, transparency and clarity in reporting are important. In addition, outside of economic evaluations conducted alongside clinical trials, there are no widespread mechanisms for warehousing economic evaluation data to allow for independent interrogation, such as ethics review proceedings, regulator dossiers, or study registries. Instead, independent analysis may rely on the record keeping of individual investigators.

Even if measures to promote transparency exist, such as registries, biomedical journal editors have increasingly promoted and endorsed the use of reporting guidelines. Endorsement of guidelines by journals for randomised controlled trials has been shown to improve reporting \[[@B6]\]. The combination of the risk of making costly decisions due to poor reporting with the lack of mechanisms that promote accountability makes transparency in reporting economic evaluations especially important and a primary concern among journal editors and decision makers \[[@B3],[@B7]\].

Aim and scope
-------------

The aim of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement is to provide recommendations, in the form of a checklist, to optimise reporting of health economic evaluations. The need for a contemporary reporting guidance for economic evaluations was recently identified by researchers and biomedical journal editors \[[@B8]\]. The CHEERS statement attempts to consolidate and update previous efforts \[[@B9]-[@B20]\] into a single useful reporting guidance.

The primary audiences for the CHEERS statement are researchers reporting economic evaluations and the editors and peer reviewers evaluating their publication potential. We hope the statement (which consists of a 24 item checklist and accompanying recommendations on the minimum amount of information to be included when reporting economic evaluations) is a useful and practical tool for these audiences and will improve reporting and, in turn, health and healthcare decisions. To best understand and apply the recommendations contained within the statement, we encourage readers to access the Explanation and Elaboration Report \[[@B21]\].

Development of the CHEERS statement
-----------------------------------

The statement was developed by a task force supported by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), as part of a broader initiative to facilitate and encourage the interchange of expert knowledge and develop best practices. The CHEERS Task Force members were chosen by the chair of the task force primarily based on their longstanding academic expertise and contribution to the multidisciplinary field of health economic evaluation. In addition to four members of the task force with doctorates in economics and its sub-discipline of health economics (AHB, MD, JM, SP), members included experts in health technology assessment and decision making (FA, AHB, DH, MD, JM) and in clinical epidemiology and biostatistics (AHB, EL, DM), those in active clinical practice (EL, FA), and those with previous experience in reporting guideline development (MD, DM). All members are researchers in applied health and health policy, with five members currently serving as editors for journals in the field (AHB, CC, MD, DG, EL).

The CHEERS Task Force followed current recommendations for developing reporting guidelines \[[@B22]\]. Briefly, the need for new guidance was first identified through a survey of members of the World Association of Medical Editors. Of the 6% (55/965) who responded, 91% (n = 50) indicated they would use a standard if one were widely available \[[@B8]\]. Next, published checklists or guidance documents related to reporting economic evaluations were identified from a systematic review and survey of task force members \[[@B23]\]. Both of these activities were used to create a preliminary list of items to include when reporting economic evaluations. Recommendations of the minimum set of reporting items were then developed through a modified Delphi panel process. Forty eight individuals identified by the task force with broad geographical representation and representing academia, biomedical journal editors, the pharmaceutical industry, government decision makers, and those in clinical practice were invited to participate. Thirty seven agreed to participate. Participants were asked to score importance on a Likert scale and the average scores, weighted by each individual's confidence in ability to score, were then used to rank items. A cut-off point was applied to the ranked list to determine the minimum number of items important for reporting.

The CHEERS statement recommendations have been independently reviewed and subsequently revised by task force members. The recommendations are entirely those of the task force---the sponsors of the study had no role in study design, data analysis, data interpretation, or writing of the final recommendations. A more complete description of the methods and findings of the Delphi panel are found in the larger explanation and elaboration document \[[@B21]\].

Checklist items
---------------

The final recommendations are subdivided into six main categories: (1) title and abstract; (2) introduction; (3) methods; (4) results; (5) discussion; and (6) other. The recommendations are contained in a user friendly, 24 item checklist (Table [1](#T1){ref-type="table"}) to aid users who wish to follow them. A copy of the checklist can also be found on the CHEERS Task Force website. (<http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp>). In order to encourage dissemination and use of a single international standard for reporting, the task force approached 14 journals identified as either the largest publishers of economic evaluations or widely read by the medical and research community. Thirteen journals responded, and 10 expressed their ability and interest in endorsing this guidance. The CHEERS statement is being simultaneously published in *BMC Medicine*, *BMJ*, *BJOG: An International Journal of Obstetrics and Gynaecology*, *Clinical Therapeutics*, *Cost Effectiveness and Resource Allocation*, *The European Journal of Health Economics*, *International Journal of Technology Assessment in Health Care*, *Journal of Medical Economics*, *Pharmacoeconomics*, and *Value in Health*. To facilitate wider dissemination and uptake of this reporting guidance, we encourage other journals and groups to consider endorsing CHEERS.

###### 

CHEERS checklist---Items to include when reporting economic evaluations of health interventions

  **Section/item**                                                       **Item No**   **Recommendation**                                                                                                                                                                                                                                                                                                                                      **Reported on page No/ line No**
  ---------------------------------------------------------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------
  **Title and abstract**                                                                                                                                                                                                                                                                                                                                                                                                                        
  Title                                                                  1             Identify the study as an economic evaluation or use more specific terms such as "cost-effectiveness analysis", and describe the interventions compared.                                                                                                                                                                                                 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Abstract                                                               2             Provide a structured summary of objectives, perspective, setting, methods (including study design and inputs), results (including base case and uncertainty analyses), and conclusions.                                                                                                                                                                 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  **Introduction**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Background and objectives                                              3             Provide an explicit statement of the broader context for the study.                                                                                                                                                                                                                                                                                      
                                                                                       Present the study question and its relevance for health policy or practice decisions.                                                                                                                                                                                                                                                                   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  **Methods**                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Target population and subgroups                                        4             Describe characteristics of the base case population and subgroups analysed, including why they were chosen.                                                                                                                                                                                                                                            \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Setting and location                                                   5             State relevant aspects of the system(s) in which the decision(s) need(s) to be made.                                                                                                                                                                                                                                                                    \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Study perspective                                                      6             Describe the perspective of the study and relate this to the costs being evaluated.                                                                                                                                                                                                                                                                     \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Comparators                                                            7             Describe the interventions or strategies being compared and state why they were chosen.                                                                                                                                                                                                                                                                 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Time horizon                                                           8             State the time horizon(s) over which costs and consequences are being evaluated and say why appropriate.                                                                                                                                                                                                                                                \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Discount rate                                                          9             Report the choice of discount rate(s) used for costs and outcomes and say why appropriate.                                                                                                                                                                                                                                                              \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Choice of health outcomes                                              10            Describe what outcomes were used as the measure(s) of benefit in the evaluation and their relevance for the type of analysis performed.                                                                                                                                                                                                                 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Measurement of effectiveness                                           11a           *Single study-based estimates:* Describe fully the design features of the single effectiveness study and why the single study was a sufficient source of clinical effectiveness data.                                                                                                                                                                   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
                                                                         11b           *Synthesis-based estimates:* Describe fully the methods used for identification of included studies and synthesis of clinical effectiveness data.                                                                                                                                                                                                       \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Measurement and valuation of preference based outcomes                 12            If applicable, describe the population and methods used to elicit preferences for outcomes.                                                                                                                                                                                                                                                             \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Estimating resources and costs                                         13a           *Single study-based economic evaluation:* Describe approaches used to estimate resource use associated with the alternative interventions. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.                                  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
                                                                         13b           *Model-based economic evaluation:* Describe approaches and data sources used to estimate resource use associated with model health states. Describe primary or secondary research methods for valuing each resource item in terms of its unit cost. Describe any adjustments made to approximate to opportunity costs.                                  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Currency, price date, and conversion                                   14            Report the dates of the estimated resource quantities and unit costs. Describe methods for adjusting estimated unit costs to the year of reported costs if necessary. Describe methods for converting costs into a common currency base and the exchange rate.                                                                                          \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Choice of model                                                        15            Describe and give reasons for the specific type of decision-analytical model used. Providing a figure to show model structure is strongly recommended.                                                                                                                                                                                                  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Assumptions                                                            16            Describe all structural or other assumptions underpinning the decision-analytical model.                                                                                                                                                                                                                                                                \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Analytical methods                                                     17            Describe all analytical methods supporting the evaluation. This could include methods for dealing with skewed, missing, or censored data; extrapolation methods; methods for pooling data; approaches to validate or make adjustments (such as half cycle corrections) to a model; and methods for handling population heterogeneity and uncertainty.   \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  **Results**                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Study parameters                                                       18            Report the values, ranges, references, and, if used, probability distributions for all parameters. Report reasons or sources for distributions used to represent uncertainty where appropriate. Providing a table to show the input values is strongly recommended.                                                                                     \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Incremental costs and outcomes                                         19            For each intervention, report mean values for the main categories of estimated costs and outcomes of interest, as well as mean differences between the comparator groups. If applicable, report incremental cost-effectiveness ratios.                                                                                                                  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Characterising uncertainty                                             20a           *Single study-based economic evaluation:* Describe the effects of sampling uncertainty for the estimated incremental cost and incremental effectiveness parameters, together with the impact of methodological assumptions (such as discount rate, study perspective).                                                                                  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
                                                                         20b           *Model-based economic evaluation:* Describe the effects on the results of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions.                                                                                                                                                                  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Characterising heterogeneity                                           21            If applicable, report differences in costs, outcomes, or cost-effectiveness that can be explained by variations between subgroups of patients with different baseline characteristics or other observed variability in effects that are not reducible by more information.                                                                              \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  **Discussion**                                                                                                                                                                                                                                                                                                                                                                                                                               
  Study findings, limitations, generalisability, and current knowledge   22            Summarise key study findings and describe how they support the conclusions reached. Discuss limitations and the generalisability of the findings and how the findings fit with current knowledge.                                                                                                                                                       \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  **Other**                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Source of funding                                                      23            Describe how the study was funded and the role of the funder in the identification, design, conduct, and reporting of the analysis. Describe other non-monetary sources of support.                                                                                                                                                                     \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
  Conflicts of interest                                                  24            Describe any potential for conflict of interest of study contributors in accordance with journal policy. In the absence of a journal policy, we recommend authors comply with International Committee of Medical Journal Editors recommendations.                                                                                                       \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

For consistency, the CHEERS statement checklist format is based on the format of the CONSORT statement checklist.

Concluding remarks
------------------

As the number of published health economic evaluations continues to grow, we believe more transparent and complete reporting of methods and findings will be increasingly important to facilitate interpretation and comparison of studies. We hope the CHEERS statement, consisting of recommendations in a 24 item checklist, will be viewed as an effective consolidation and update of previous efforts and serve as a starting point for standard reporting going forward.

We believe the CHEERS statement represents a considerable expansion over previous efforts. The strength of our approach is that it was developed in accordance with current recommendations for the development of reporting guidelines, using an international and multidisciplinary team of editors and content experts in economic evaluation and reporting \[[@B22]\]. Similar to the approach taken with other widely accepted guidelines, we have defined a minimum set of criteria though a modified Delphi technique and have translated these into recommendations, an explanatory document with explanations, and a checklist. Unlike some previous reporting guidance for economic evaluation, we have also made every effort to be neutral about the conduct of economic evaluation, allowing analysts the freedom to choose different methods.

There may be several limitations to our approach. A larger Delphi panel with a different composition could have led to a different final set of recommendations \[[@B24]\]. Some less common approaches and contexts (such as public health, developing countries, and system dynamic models) for conducting health economic evaluation may not be well represented by our sample of experts. Additionally, like many Delphi panel processes, we based decisions to reject or accept criteria on arbitrary levels of importance. However, we feel the group recruited to create the statement is sufficiently knowledgeable of the more common applications of economic evaluation, and the rules used to select criteria were created a priori and are consistent with previous efforts.

We believe it will be important to evaluate the effects of implementation of this statement and checklist on reporting in future economic evaluations. As methods for the conduct of economic evaluation continue to evolve, it will also be important to revisit or extend the guidance. The CHEERS Task Force feels that this statement should be reviewed for updating five years from its release.
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